Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)
E I Tarlovskaya,A G Arutyunov,A O Konradi,Yu M Lopatin,A P Rebrov,S N Tereshchenko,A I Chesnikova,H G Hayrapetyan,A P Babin,I G Bakulin,N V Bakulina,L A Balykova,A S Blagonravova,M V Boldina,A R Vaisberg,A S Galyavich,V V Gomonova,N Yu Grigorieva,I V Gubareva,I V Demko,A V Evzerikhina,A V Zharkov,U K Kamilova,Z F Kim,T Yu Kuznetsova,N V Lareva,E V Makarova,S V Malchikova,S V Nedogoda,M M Petrova,I G Pochinka,K V Protasov,D N Protsenko,D Yu Ruzanau,S A Sayganov,A S Sarybaev,N M Selezneva,A B Sugraliev,I V Fomin,O V Khlynova,O Yu Chizhova,I I Shaposhnik,D A Shсukarev,A K Abdrahmanova,S A Avetisian,H G Avoyan,K K Azarian,G T Aimakhanova,D A Ayipova,A Ch Akunov,M K Alieva,A V Aparkina,O R Aruslanova,E Yu Ashina,O Yu Badina,O Yu Barisheva,A S Batchayeva,A M Bitieva,I U Bikhteyev,N A Borodulina,M V Bragin,A M Budu,L A Burygina,G A Bykova,K R Vagapova,D D Varlamova,N N Vezikova,E A Verbitskaya,O E Vilkova,E A Vinnikova,V V Vustina,E A Gаlova,V V Genkel,E I Gorshenina,R V Gostishev,E V Grigorieva,E Yu Gubareva,G M Dabylova,A I Demchenko,O Yu Dolgikh,M Y Duyshobayev,D S Evdokimov,K E Egorova,A N Ermilova,A E Zheldybayeva,N V Zarechnova,Yu D Zimina,S Yu Ivanova,E Yu Ivanchenko,M V Ilina,M V Kazakovtseva,E V Kazymova,Yu S Kalinina,N A Kamardina,A M Karachenova,I A Karetnikov,N A Karoli,O V Karpov,M Kh Karsiev,D S Кaskaeva,K F Kasymova,Zh B Kerimbekova,A Sh Kerimova,E S Kim,N V Kiseleva,D A Klimenko,A V Klimova,O V Kovalishena,E V Kolmakova,T P Kolchinskaya,M I Kolyadich,O V Kondriakova,M P Konoval,D Yu Konstantinov,E A Konstantinova,V A Kordukova,E V Koroleva,A Yu Kraposhina,T V Kriukova,A S Kuznetsova,T Yu Kuzmina,K V Kuzmichev,Ch K Kulchoroeva,T V Kuprina,I M Kouranova,L V Kurenkova,N Yu Kurchugina,N A Kushubakova,V I Levankova,M Е Levin,N A Lyubavina,N A Magdeyeva,K V Mazalov,V I Majseenko,A S Makarova,A M Maripov,A A Marusina,E S Melnikov,N B Moiseenko,F N Muradova,R G Muradyan,A O Myshak,N M Nikitina,B B Ogurlieva,A A Odegova,Yu M Omarova,N A Omurzakova,Sh O Ospanova,E V Pahomova,L D Petrov,S S Plastinina,V A Pogrebetskaya,D S Polyakov,E V Ponomarenko,L L Popova,N A Prokofeva,I A Pudova,N A Rakov,A N Rakhimov,N A Rozanova,S Serikbolkyzy,A A Simonov,V V Skachkova,D V Soloveva,I A Soloveva,F M Sokhova,A K Subbotin,I M Sukhomlinova,A G Sushilova,D R Tagayeva,Yu V Titojkina,E P Tikhonova,D S Tokmin,A A Tolmacheva,M S Torgunakova,K V Trenogina,N A Trostianetckaia,D A Trofimov,A A Tulichev,A T Tursunova,N D Ulanova,O V Fatenkov,O V Fedorishina,T S Fil,I Yu Fomina,I S Fominova,I A Frolova,S M Tsvinger,V V Tsoma,M B Cholponbaeva,T I Chudinovskikh,O A Shevchenko,T V Sheshina,E A Shishkina,K Yu Shishkov,S Yu Sherbakov,E A Yausheva,Sh N Musaelian,Yu N Belenkov,G P Arutyunov
DOI: https://doi.org/10.18087/cardio.2021.9.n1680
2021-09-30
Kardiologiia
Abstract:Aim To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment).Results The analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD).Conclusion In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.